Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome
- PMID: 19072461
- DOI: 10.2217/17455057.4.6.583
Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome
Abstract
Polycystic ovary syndrome (PCOS) is associated with a clustering of metabolic and cardiovascular risk factors. Insulin resistance is implicated as the major player in the metabolic abnormalities and contributes to the increased cardiovascular risk associated with the syndrome. However, androgen excess appears to participate as an independent parameter, which further aggravates the cardiovascular and metabolic aberrations in affected women with PCOS. The resultant impact of hyperandrogenemia possibly acquires clinical significance for women's health in the context of PCOS, particularly since recent data support an increased incidence of coronary artery disease and of cardiovascular events directly related to androgen levels in women with the syndrome.
Similar articles
-
Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome.Fertil Steril. 2015 Mar;103(3):795-801.e2. doi: 10.1016/j.fertnstert.2014.12.105. Epub 2015 Jan 10. Fertil Steril. 2015. PMID: 25585504
-
Arterial stiffness is increased in asymptomatic nondiabetic postmenopausal women with a polycystic ovary syndrome phenotype.J Hypertens. 2013 Oct;31(10):1998-2004. doi: 10.1097/HJH.0b013e3283630362. J Hypertens. 2013. PMID: 24107731
-
Androgens and polycystic ovary syndrome.Curr Opin Endocrinol Diabetes Obes. 2009 Jun;16(3):224-31. doi: 10.1097/MED.0b013e32832afd4d. Curr Opin Endocrinol Diabetes Obes. 2009. PMID: 19390322 Review.
-
Cardiovascular risk factors and events in women with androgen excess.J Endocrinol Invest. 2015 Mar;38(3):295-301. doi: 10.1007/s40618-014-0215-1. Epub 2014 Nov 29. J Endocrinol Invest. 2015. PMID: 25432327 Review.
-
Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome.Maturitas. 2011 Jan;68(1):13-6. doi: 10.1016/j.maturitas.2010.09.005. Epub 2010 Oct 12. Maturitas. 2011. PMID: 20943333 Review.
Cited by
-
Cardiovascular disease markers in women with polycystic ovary syndrome with emphasis on asymmetric dimethylarginine and homocysteine.Ann Saudi Med. 2010 Jul-Aug;30(4):278-83. doi: 10.4103/0256-4947.65255. Ann Saudi Med. 2010. PMID: 20622344 Free PMC article.
-
Cardiovascular-renal and metabolic characterization of a rat model of polycystic ovary syndrome.Gend Med. 2011 Apr;8(2):103-15. doi: 10.1016/j.genm.2010.11.013. Gend Med. 2011. PMID: 21536229 Free PMC article.
-
Beneficial Effects of Alchemilla vulgaris in DHEA-Induced Rat Model of Polycystic Ovary Syndrome.Reprod Sci. 2025 Jul;32(7):2453-2466. doi: 10.1007/s43032-025-01885-9. Epub 2025 Jun 23. Reprod Sci. 2025. PMID: 40550985 Free PMC article.
-
Age at Menarche and Menopause, Reproductive Lifespan, and Risk of Cardiovascular Events Among Chinese Postmenopausal Women: Results From a Large National Representative Cohort Study.Front Cardiovasc Med. 2022 Sep 9;9:870360. doi: 10.3389/fcvm.2022.870360. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36158833 Free PMC article.
-
N-acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled clinical trials.Obstet Gynecol Int. 2015;2015:817849. doi: 10.1155/2015/817849. Epub 2015 Jan 8. Obstet Gynecol Int. 2015. PMID: 25653680 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical